

## PHARMACY SERVICES

1// 11/ 10/01

# 2019 Valuation Report

January 2020

BOURNE PARTNERS

#### **Comp./Spec.** Pharmacy – Transaction Comps

| DecisitWeight specific proposition of a plant specific proposition plant spe | Dec-19 |                                | Target Description  | Buyer                         | Geographic<br>Location | Enterprise<br>Value | LTM Revenue | LTM EBITDA | EV / LTM<br>Revenue | EV / LTM<br>EBITDA |
|--|--------|--------------------------------|---|-------------------------------|------------------------|---------------------|-------------|------------|---------------------|--------------------|
| Oct-19   KnippeRk Inc.   Operates as an independent specially pharmacy chain, offering court Square Capital Partners   USA   NA  |        | Pharmacy and Infusion Services |   | BrightSpring Health Services  | USA                    | NA                  | NA          | NA         | NA                  | NA                 |
| Oct-19 Knippetk Inc. nare, ophan, and ultra ophan dug categories Court Square Capital Pathens USA NA   | Dec-19 | Diplomat Pharmacy, Inc.        | Independent specialty pharmacy and PBM for the US   | OptumRx, Inc.                 |                        | \$897.3             | \$5,206.3   | \$54.3     | 0.2x                | 16.5x              |
| Mdly 19   Beind / Marmacy   specific preparations of various pharmaceutical products   Webster Equity Parmers   USA   NA  | Oct-19 | KnippeRx Inc.                  |   | Court Square Capital Partners | USA                    | NA                  | NA          | NA         | NA                  | NA                 |
| MSY-19   Assets of Premier, Inc.   related assets of Premier, Inc.   Procare Pharmacy, LLC.   USA   42.3   NA   | May-19 | Belmar Pharmacy                |   |                               | USA                    | NA                  | NA          | NA         | NA                  | NA                 |
| March March March   United States   Option Care Health, Inc.   USA   NA   NA </td <td>May-19</td> <td></td> <td></td> <td>Procare Pharmacy, L.L.C.</td> <td>USA</td> <td>42.3</td> <td>NA</td> <td>NA</td> <td>NA</td> <td>NA</td>   | May-19 |                                |   | Procare Pharmacy, L.L.C.      | USA                    | 42.3                | NA          | NA         | NA                  | NA                 |
| Oct-18Aveila Specialty PharmacyAveila Specialty PharmacyNA   | Mar-19 | BioScrip, Inc.                 |   | Option Care Health, Inc.      | USA                    | NA                  | NA          | NA         | NA                  | NA                 |
| Aug-17   Quantum Pharma Plc   Develops, manufactures, and supplies niche pharmaceutical wholesaler, hospital, and homecare markets   Clinigen Group plc   United Kingdom   199.9   119.5   8.2   1.7x   24.4x     Apr-16   Diplomat Specialty Pharmacy of Los Angeles County, Inc.   Stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers   Diplomat Pharmacy, Inc.   USA   75.7   400.0   9.0   NM   8.4x     Apr-16   Integrity Compounding Pharmacy, LLC   Develops and provides compounded pharmaceutical products   True Nature Holding, Inc.   USA   1.0   0.9   NA   1.1x   NA     otes:   Verticity   S59.0   S259.8   S8.6   1.1x   12.5x  | Oct-18 | Avella Specialty Pharmacy      |   | OptumRx / UnitedHealth Group  | USA                    | NA                  | NA          | NA         | NA                  | NA                 |
| Aug-17   Quantum Pharma Plc   products to the retail pharmacy, pharmaceutical wholesaler, bospital, and homecare markets   Clinigen Group plc   United Kingdom   199.9   119.5   8.2   1.7x   24.4x     Apr-16   Diplomat Specialty Pharmacy of Stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers   Diplomat Pharmacy, Inc.   USA   75.7   400.0   9.0   NM   8.4x     Apr-16   Integrity Compounding Pharmacy, LLC   Develops and provides compounded pharmaceutical products   True Nature Holding, Inc.   USA   1.0   0.9   NA   1.1x   NA     otes:    S59.0   \$259.8   \$8.6   1.1x   12.5x  | Nov-17 | Salus Pharmacare Inc.          | Specialty pharmacy offering medication management services to<br>assisted living and LTC facilities | Centric Health Corporation    | Canada                 | 3.2                 |             | 0.5        |                     | 6.8x               |
| Apr-16   Los Angeles County, Inc.   biotechnology and speciality pharmaceutical manufacturers   Diplomat Pharmacy, Inc.   USA   75.7   400.0   9.0   NM   8.4x     Apr-16   Integrity Compounding<br>Pharmacy, LLC   Develops and provides compounded pharmaceutical products   True Nature Holding, Inc.   USA   1.0   0.9   NA   1.1x   NA     otes:   Median   \$59.0   \$259.8   \$8.6   1.1x   12.5x  | Aug-17 | Quantum Pharma Plc             | products to the retail pharmacy, pharmaceutical wholesaler,   | Clinigen Group plc            | United Kingdom         | 199.9               | 119.5       | 8.2        | 1.7x                | 24.4x              |
| Apr-16 Pharmacy, LLC Develops and provides compounded pharmaceutical products True Nature Holding, Inc. USA 1.0 0.9 NA 1.1x NA   | Apr-16 |                                |   | Diplomat Pharmacy, Inc.       |                        | 75.7                | 400.0       | 9.0        | NM                  | 8.4x               |
|  | Apr-16 |                                | Develops and provides compounded pharmaceutical products  | True Nature Holding, Inc.     | USA                    | 1.0                 | 0.9         | NA         | 1.1x                | NA                 |
| A - Not Available Mean 203.2 1,431.7 18.0 1.0x 14.0x   | lotes: |                                |   |                               | Median                 | \$59.0              | \$259.8     | \$8.6      | 1.1x                | 12.5x              |
|  |        | hle                            |   |                               | Mean                   | 203.2               | 1,431.7     | 18.0       | 1.0x                | 14.0x              |

#### BOURNE PARTNERS

Max

897.3

5,206.3

54.3

#### **PBM/Managed Care – Transaction Comps**

|                                      |   | PBM/Manage   | d Care – Transa              | ction Com              | ps                  |             |            |                     |                    |
|--------------------------------------|---|--|------------------------------|------------------------|---------------------|-------------|------------|---------------------|--------------------|
| USD in millions<br>Announced<br>Date | Target  | Target Description   | Buyer                        | Geographic<br>Location | Enterprise<br>Value | LTM Revenue | LTM EBITDA | EV / LTM<br>Revenue | EV / LTM<br>EBITDA |
| Dec-19                               | Enclara Pharmacia, Inc.                       | Full service mail order supplier of medications and clinical services and PBM, primarily focused on hospice and palliative care industries       | Humana Inc.                  | USA                    | NA                  | NA          | NA         | NA                  | NA                 |
| Dec-19                               |   |  |                              |                        |                     |             |            |                     | 16.5x              |
| Mar-19                               | WellCare Health Plans, Inc.                   | Provides government-sponsored managed care services  | Centene Corporation          | USA                    | 17,300.0            | 20,414.1    | 915.2      | 0.8x                | 18.9x              |
| Sep-18                               |   |  |                              |                        |                     |             |            |                     | NA                 |
| Aug-18                               | Excel Managed Care & Disability Services Inc. | Provides occupational and non-occupational medical case<br>management, utilization review, and return-to-work services                           | Genex Services, LLC          | USA                    | NA                  | NA          | NA         | NA                  | NA                 |
| Mar-18                               |   | RxAdvance is a national full-service PBM that helps to manage<br>standard formulary, specialty pharmaceutical, and biologics<br>usage            |                              |                        |                     |             |            |                     | NA                 |
| Mar-18                               | Express Scripts Holding<br>Company            | Express Scripts is one of the largest PBMs in the US   | Cigna Corporation            | USA                    | 68,671.4            | 100,064.6   | 7,132.5    | 0.7x                | 9.6x               |
| Dec-17                               |   |  |                              |                        |                     |             |            |                     | 12.3x              |
| Nov-17                               | Leehar Distributors, Inc.                     | Provides pharmacy benefits services for health insurance agent<br>and consultants; third party administrators; and self-insured<br>organizations | s<br>Diplomat Pharmacy, Inc. | USA                    | 595.6               | NA          | NA         | NA                  | NA                 |
| Nov-17                               |   |  |                              |                        |                     |             |            |                     | 8.7x               |
| Nov-16                               | Integrated Prescription<br>Solutions, Inc.    | Provides PBM and ancillary healthcare services in the US   | Mitchell International, Inc. | USA                    | NA                  | NA          | NA         | NA                  | NA                 |
| Jan-16                               |   |  |                              |                        | 1,600.0             | NA          | NA         | NA                  | NA                 |
| Notes:                               |   |  |                              | Median                 | \$2,050.0           | \$20,414.1  | \$915.2    | 0.8x                | 12.3x              |
| NA - Not Availab                     | le  |  |                              | Mean                   | 20,156.8            | 37,250.4    | 2,758.5    | 0.9x                | 13.2x              |

NM - Not Meaningful

47.0

69,643.0

32.0

100,064.6

5.4 7,132.5

Min

Max

### **Comp./Spec.** Pharmacy – Trading Comps

|                         |               | Comp                | oundin  | g/Speci | alty Ph | armac           | y – Trad | ing Cor | nps               |        |       |                     |                 |        |
|-------------------------|---------------|---------------------|---------|---------|---------|-----------------|----------|---------|-------------------|--------|-------|---------------------|-----------------|--------|
| USD in millions         |               |                     | LTM     |         |         | Margin Analysis |          |         | Enterprise Value/ |        |       | Debt/               |                 |        |
| Company                 | Ticker        | Enterprise<br>Value | Sales   | EBITDA  | EBIT    | Gross<br>Profit | EBITDA   | EBIT    | Sales             | EBITDA | EBIT  | Enterprise<br>Value | Equity<br>Value | EBITDA |
| Diplomat Pharmacy, Inc. | NYSE:DPLO     | 881.3               | 5,206.3 | 54.3    | (6.4)   | 6.0%            | 1.0%     | NM      | 0.2x              | 16.2x  | NM    | 66.6%               | 193.5%          | 10.8x  |
| Fagron NV               | ENXTBR:FAGR   | 1,878.6             | 564.6   | 101.9   | 90.2    | 44.9%           | 18.1%    | 16.0%   | 3.3x              | 18.4x  | 20.8x | 22.6%               | 27.1%           | 4.2x   |
| Harrow Health, Inc.     | NasdaqCM:HROW | 190.4               | 49.9    | (1.2)   | (3.2)   | 65.4%           | NM       | NM      | 3.8x              | NM     | NM    | 10.6%               | 10.3%           | NM     |
|                         |               |                     |         |         | Median  | 44.9%           | 9.5%     | 16.0%   | 3.3x              | 17.3x  | 20.8x | 22.6%               | 27.1%           | 7.5x   |
|                         |               |                     |         |         | Mean    | 38.8%           | 9.5%     | 16.0%   | 2.4x              | 17.3x  | 20.8x | 33.2%               | 77.0%           | 7.5x   |
|                         |               |                     |         |         | Min     | 6.0%            | 1.0%     | 16.0%   | 0.2x              | 16.2x  | 20.8x | 10.6%               | 10.3%           | 4.2x   |
|                         |               |                     |         |         | Max     | 65.4%           | 18.1%    | 16.0%   | 3.8x              | 18.4x  | 20.8x | 66.6%               | 193.5%          | 10.8x  |


- Few publicly traded Compounding/Specialty Pharmacies exist on the market today
- As these markets continue to mature and experience consolidation, we expect to see more companies looking to the public markets as a capital source
- Q4 2019 was marked by Optum's acquisition of Diplomat Pharmacy in December
  - Under the agreement, Optum will pay Diplomat \$300mm in cash (\$4.00 per share) and assume more than \$560mm in debt
  - This remains consistent with UnitedHealth Group's strategy of acquiring more medical care providers and services through its Optum unit
    - Optum is expected to contribute more than half of UnitedHealth's profits in 2020
- As of the end of Q4, the median EV multiples for this sector were 3.3x and 17.3x for LTM Sales and EBITDA, respectively

### **PBM/Managed Care – Trading Comps**

| USD in millions                 |           | _                   | LTM         |           |           | Margin Analysis |        |      | Enterprise Value/ |        |       | Debt/               |                 |        |
|---------------------------------|-----------|---------------------|-------------|-----------|-----------|-----------------|--------|------|-------------------|--------|-------|---------------------|-----------------|--------|
| Company                         | Ticker    | Enterprise<br>Value | Sales       | EBITDA    | EBIT      | Gross<br>Profit | EBITDA | EBIT | Sales             | EBITDA | EBIT  | Enterprise<br>Value | Equity<br>Value | EBITDA |
| Anthem, Inc.                    | NYSE:ANTM | \$93,728.8          | \$100,165.0 | \$6,742.0 | \$6,154.0 | 20.8%           | 6.7%   | 6.1% | 0.9x              | 13.9x  | 15.2x | 22.8%               | 27.9%           | 3.2    |
| Centene Corporation             | NYSE:CNC  |                     | 68,369.0    | 3,208.0   |           |                 |        | 3.8% |                   | 8.6x   |       |                     |                 |        |
| Cigna Corporation               | NYSE:CI   | 111,194.8           | 129,660.0   | 10,497.0  | 7,855.0   | 17.8%           | 8.1%   | 6.1% | 0.9x              | 10.6x  | 14.2x | 35.4%               | 51.6%           | 3.8    |
| CVS Health Corporation          | NYSE:CVS  | 178,799.6           | 243,331.0   | 15,751.0  | 11,669.0  | 17.5%           | 6.5%   | 4.8% | 0.7x              | 11.4x  | 15.3x | 50.2%               | 92.8%           | 5.7    |
| Humana Inc.                     | NYSE:HUM  | 49,790.8            | 62,761.0    | 3,618.0   | 3,366.0   | 17.8%           | 5.8%   | 5.4% | 0.8x              | 13.8x  | 14.8x | 13.6%               | 14.0%           | 1.9    |
| UnitedHealth Group Incorporated | NYSE:UNH  | 311,052.0           | 239,671.0   | 21,120.0  | 19,087.0  | 23.5%           | 8.8%   | 8.0% | 1.3x              | 14.7x  | 16.3x | 14.4%               | 16.1%           | 2.1    |
| WellCare Health Plans, Inc.     | NYSE:WCG  | 16,349.2            | 26,983.3    | 1,173.3   | 991.9     | 13.0%           | 4.3%   | 3.7% | 0.6x              | 13.9x  | 16.5x | 14.1%               | 13.8%           | 2.0    |
|                                 |           |                     |             |           | Median    | 17.8%           | 6.5%   | 5.4% | 0.8x              | 13.8x  | 15.2x | 22.8%               | 27.9%           | 2.4    |
|                                 |           |                     |             |           | Mean      | 18.2%           | 6.4%   | 5.4% | 0.8x              | 12.4x  | 14.7x | 25.5%               | 35.2%           | 3.0    |
|                                 |           |                     |             |           | Min       | 13.0%           | 4.3%   | 3.7% | 0.4x              | 8.6x   | 10.7x | 13.6%               | 13.8%           | 1.9    |
|                                 |           |                     |             |           | Max       | 23.5%           | 8.8%   | 8.0% | 1.3x              | 14.7x  | 16.5x | 50.2%               | 92.8%           | 5.7    |

- As mentioned on the previous slide, Q4 was marked by UnitedHealth's Optum unit continuing its flurry of acquisitions in the medical care and specialty pharmacy spaces
- Following the same trend as the year prior, 2019 was marked by its own mega-deal the \$17.3bn proposed acquisition of WellCare Health Plans by Centene Corporation – highlighting an ever-increasing focus on consolidation within this industry segment
  - The spike in M&A over the last handful of years has driven valuations and will likely continue to do so within the PBM/Managed Care segment as firms look to add niche services and compile more lives
- As of the end of Q4, the median EV multiples for this segment were 0.8x and 13.8x for LTM Sales and EBITDA, respectively

#### Valuation Trends – Last 3 Years



- The PBM/Managed Care segment stayed fairly steady in Q4, holding just below the S&P 500 index
  - As of the end of Q4, the sector was sitting at 12.9x LTM EBITDA
- The Compounding/Specialty Pharmacy index saw a slight lift over the last quarter but is still short of 2018 highs
  - As of the end of Q4, the sector was sitting at 18.2x LTM EBITDA

Comp./Spec. Pharmacy basket consists of: Diplomat Pharmacy, Inc. (NYSE:DPLO), Fagron NV (ENXTBR:FAGR), and Harrow Health, Inc. (NasdaqCM:HROW) PBM/Managed Care basket consists of: Anthem, Inc. (NYSE:ANTM), Centene Corporation (NYSE:CNC), Cigna Corporation (NYSE:CI), CVS Health Corporation (NYSE:CVS), Humana Inc. (NYSE:HUM), UnitedHealth Group Incorporated (NYSE:UNH), WellCare Health Plans, Inc. (NYSE:WCG)



#### Valuation Trends (Current, 3 Year, & LTM Comparisons)

- Below are the current TEV / EBITDA multiples for each sector as of the end of Q4:
  - Compounding/Specialty Pharmacy: 18.2x (29.2% above current S&P multiple)
  - PBM/Managed Care: 12.9x (8.9% below current S&P multiple)
  - S&P 500: 14.1x
- Below are the average TEV / EBITDA multiples for each sector over the last 3 years:
  - Compounding/Specialty Pharmacy: 18.5x (47.1% above average S&P multiple)
  - PBM/Managed Care: 11.6x (7.2% below average S&P multiple)
  - S&P 500: 12.5x
- Below are the % change in TEV / EBITDA multiples for each sector over the last 3 years (and LTM):
  - Compounding/Specialty Pharmacy: +13.5% (up 1.7% in the last 12 months)
  - PBM/Managed Care: +23.5% (up 5.4% in the last 12 months)
  - S&P 500: +19.9% (up 24.1% in the last 12 months)